All patients
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Immunostimulants drugs in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.64 [0.43 ; 0.95 ] Pandit, 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 0% 1,486 moderate not evaluable deathsdetailed results Fu, 2020 1.00 [0.02; 51.66]
Libster, 2020 0.50 [0.09; 2.71]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.63 [0.43 ; 0.93 ] Fu, 2020, Libster, 2020, Pandit, 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 5 0% 1,726 moderate not evaluable clinical deteriorationdetailed results Libster, 2020 0.52 [0.29; 0.94]
0.52 [0.29 ; 0.94 ] Libster, 2020 1 0% 160 NA not evaluable clinical improvementdetailed results Shashi Bhushan, 2021 0.68 [0.21; 2.20]
0.68 [0.21 ; 2.20 ] Shashi Bhushan, 2021 1 0% 242 NA not evaluable clinical improvement (14-day)detailed results Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
2.03 [0.17 ; 24.32 ] Pandit, 2021, Shashi Bhushan, 2021 2 75% 281 moderate not evaluable clinical improvement (7-day)detailed results Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.91 [1.03 ; 3.53 ] Shashi Bhushan, 2021 1 0% 222 NA not evaluable death or ventilationdetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.66 [0.46 ; 0.94 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable hospital dischargedetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.48 [1.05 ; 2.09 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.61 [0.61 ; 4.25 ] Jagannathan, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 82% 401 moderate not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance by day 14detailed results Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.18 [0.00 ; 435.69 ] Pandit, 2021, Shashi Bhushan, 2021 2 98% 1,359 moderate not evaluable viral clearance by day 7detailed results Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.69 [1.48 ; 4.87 ] Pandit, 2021, Shashi Bhushan, 2021 2 0% 281 moderate not evaluable ICU admissiondetailed results Libster, 2020 0.33 [0.07; 1.58]
0.33 [0.07 ; 1.58 ] Libster, 2020 1 0% 160 NA not evaluable serious adverse eventsdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
Pandit, 2021 0.95 [0.02; 50.33]
0.99 [0.17 ; 5.88 ] Jagannathan, 2020, Pandit, 2021 2 0% 159 moderate not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
Pandit, 2021 1.68 [0.47; 5.97]
1.41 [0.74 ; 2.67 ] Jagannathan, 2020, Pandit, 2021 2 0% 159 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 15:43 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567
- roots T: 290
